Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Moving toward disease modification in polycythemia vera
Jan Philipp Bewersdorf
, Joan How
, Lucia Masarova
, Prithviraj Bose
, Naveen Pemmaraju
,
John Mascarenhas
, Raajit K. Rampal
Center for Advancement of Blood Cancer Therapies
Cancer Clinical Investigation
Graduate School of Biomedical Sciences
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Hematology and Medical Oncology
Mount Sinai Tisch Cancer Center
Research output
:
Contribution to journal
›
Comment/debate
26
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Moving toward disease modification in polycythemia vera'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Disease Modification
100%
Polycythemia Vera
100%
Molecular Response
60%
Phlebotomy
60%
Low Risk
40%
Thrombosis
40%
Acute Myeloid Leukemia
40%
Cytoreductive Surgery
40%
Myelofibrosis
40%
Interferon-α (IFN-α)
20%
Early Treatment
20%
Aspirin
20%
Treatment Modalities
20%
Treatment Strategy
20%
Systemic Symptoms
20%
High-risk Disease
20%
Natural History
20%
Disease Symptoms
20%
Disease Course
20%
Long Follow-up
20%
Activating mutation
20%
Leukocytosis
20%
Low-risk Disease
20%
Disease-modifying Therapy
20%
Splenomegaly
20%
Janus Kinase 2 (JAK2)
20%
Significant Disease
20%
Interferon alpha-2b
20%
Hydroxyurea
20%
Patient-centered
20%
Intolerance
20%
Treatment Landscape
20%
Treatment Selection
20%
Clinically Meaningful Outcomes
20%
Myeloproliferative Neoplasms
20%
Thrombocytosis
20%
Limited Disease
20%
Vasomotor Symptoms
20%
Erythrocytosis
20%
Time-limited Therapy
20%
Therapeutic Phlebotomy
20%
Free Treatment
20%
Disease Features
20%
Medicine and Dentistry
Polycythemia vera
100%
Diseases
100%
Phlebotomy
57%
Thrombosis
28%
Acute Myeloid Leukemia
28%
Myelofibrosis
28%
Disease Course
14%
Acetylsalicylic Acid
14%
Thromboembolism
14%
Janus Kinase
14%
Splenomegaly
14%
Hydroxyurea
14%
Myeloproliferative Neoplasm
14%
Interferon Alfa
14%
Interferon Alfa 2b
14%
Leukocytosis
14%
Vasomotor
14%
Thrombocytosis
14%
Erythrocytosis
14%
Treatment Modality
14%
Pharmacology, Toxicology and Pharmaceutical Science
Polycythemia vera
100%
Diseases
100%
Thrombosis
28%
Acute Myeloid Leukemia
28%
Myelofibrosis
28%
Acetylsalicylic Acid
14%
Disease Course
14%
Thromboembolism
14%
Leukocytosis
14%
Janus Kinase
14%
Splenomegaly
14%
Hydroxycarbamide
14%
Alpha Interferon
14%
Myeloproliferative Neoplasm
14%
Alpha2b Interferon
14%
Thrombocytosis
14%
Erythrocytosis
14%